Serum Leptin, Resistin, and Lipid Levels in Patients with End Stage Renal Failure with Regard to Dialysis Modality

REFERENCES

• Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol. 2006; 6: 355–365
   Google Scholar
• Festa A, D'Agostino R, Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42–47
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R, Williams K, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes., 25: 1407–1415, 200
   Google Scholar
• Kaysen GA. Hyperlipidemia of chronic renal failure. Blood Purif. 1994; 12: 60–67
   Google Scholar
• Kagan A, Haran N, Leschinsky L, Shuali N, Rapoport J. Leptin in CAPD patients: serum concentrations and peritoneal loss. Nephrol Dial Transplant. 1999; 14: 400–405
   Google Scholar
• Axelsson J, Heimburger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr. 2005; 15: 131–136
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Pérez Fontán M, Rodríguez-Carmona A, Cordido F, García-Buela J. Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: a comparative analysis. Am J Kidney Dis. 1999; 34: 824–831
   PubMed Web of Science ®Google Scholar
• Rodríguez-Carmona A, Pérez Fontán M, Cordido F, García Falcón T, García-Buela J. Hyperleptinemia is not correlated with markers of protein malnutrition in chronic renal failure. Nephron. 2000; 86: 274–280
   PubMed Web of Science ®Google Scholar
• Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis. 2004; 43: 1047–1055
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int Suppl. 2003; 84: 65–68
   Google Scholar
• Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol. 2005; 62: 242–249
   PubMed Web of Science ®Google Scholar
• Ahima RS, Saper CB, Flier JS, Elmquist JK. Leptin regulation of neuroendocrine systems. Front Neuroendocrinology. 2000; 21: 263–307
   PubMed Web of Science ®Google Scholar
• Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ. Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res. 2000; 8: 530–539
   PubMedGoogle Scholar
• Wellhoener P, Fruehwald-Schultes B, Kern W, et al. Glucose metabolism rather than insulin is a main determinant of leptin secretion in humans. J Clin Endocrinol Metab. 2000; 85: 1267–1271
   PubMed Web of Science ®Google Scholar
• Mueller WM, Gregoire FM, Stanhope KL, et al. Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. Endocrinology. 1998; 139: 551–558
   PubMed Web of Science ®Google Scholar
• Moreno-Aliaga MJ, Stanhope KL, Havel PJ. Transcriptional regulation of the leptin promoter by insulin-stimulated glucose metabolism in 3t3–l1 adipocytes. Biochem Biophys Res Commun. 2001; 283: 544–548
   PubMed Web of Science ®Google Scholar
• Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991; 266(8)4706–4712, 15
   PubMed Web of Science ®Google Scholar
• Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, Garvey WT. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest. 1995; 96(6)2792–2801
   Google Scholar
• Robinson KA, Sens DA, Buse MG. Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor. Diabetes. 1993; 42(9)1333–1346
   Google Scholar
• Zhang P, Klenk ES, Lazzaro MA, Williams LB, Considine RV. Hexosamines regulate leptin production in 3T3-L1 adipocytes through transcriptional mechanisms. Endocrinology. 2002; 143(1)99–106
   Google Scholar
• Nakazono H, Nagake Y, Ichikawa H, Makino H. Serum leptin concentrations in patients on hemodialysis. Nephron. 1998; 80: 35–40
   PubMed Web of Science ®Google Scholar
• Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004; 344: 1–12
   PubMed Web of Science ®Google Scholar
• Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46: 459–469
   PubMed Web of Science ®Google Scholar
• Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003; 52: 239–243
   PubMed Web of Science ®Google Scholar
• Steppan CM, Brown EJ, Wright CM, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001; 98: 502–506
   Google Scholar
• Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity?. Diabetes Obes Metab. 2004; 6: 163–170
   PubMedGoogle Scholar
• Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003; 88: 4848–4856
   PubMed Web of Science ®Google Scholar
• Youn BS, Yu KY, Park HJ, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004; 89: 150–156
   PubMed Web of Science ®Google Scholar
• Filippidis G, Liakopoulos V, Mertens PR, et al. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif. 2005; 23: 421–428
   Google Scholar
• Bastard JP, Jardel C, Bruckert E. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000; 85: 3338–3342
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82: 4196–4200
   PubMed Web of Science ®Google Scholar
• Espinoza M, Aguilera A, Auxiliadora Bajo M, et al. Tumor necrosis factor alpha as a uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia, and hypertriglyceridemia in peritoneal dialysis patients. Adv Perit Dial. 1999; 15: 82–86
   PubMedGoogle Scholar
• Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol. 2001; 153: 1094–1101
   PubMed Web of Science ®Google Scholar
• Fujino Y, Ishimura E, Okuno S, et al. C-reactive protein is a significant predictor of decrease in fat mass in hemodialysis patients. Biomed Pharmacother. 2005; 59: 264–268
   PubMed Web of Science ®Google Scholar